Home Cart Sign in  
Chemical Structure| 18642-23-4 Chemical Structure| 18642-23-4

Structure of psoralidin
CAS No.: 18642-23-4

Chemical Structure| 18642-23-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Psoralidin, a natural furanocoumarin, is isolated from Psoralea corylifolia L. with anticancer and chemopreventive properties, inhibits Akt phosphorylation and phosphatidylinositol 3-kinase activation.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of psoralidin

CAS No. :18642-23-4
Formula : C20H16O5
M.W : 336.34
SMILES Code : O=C1C2=C(OC3=CC(O)=CC=C32)C4=C(O1)C=C(O)C(CC=C(C)C)=C4
MDL No. :MFCD10566617
InChI Key :YABIJLLNNFURIJ-UHFFFAOYSA-N
Pubchem ID :5281806

Safety of psoralidin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of psoralidin

PI3K-AKT

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
PC-3 cells 60 µM 24 hours Psoralidin inhibited viability and induced apoptosis in PC-3 cells Apoptosis. 2010 Feb;15(2):153-61
HL-1 cardiomyocytes 10, 20, 50, 100 µM 24 hours Evaluate the toxic effects of psoralidin on HL-1 cardiomyocytes, showing no significant toxicity at concentrations ≤50 μM. J Adv Res. 2022 Sep;40:249-261
Commercial breast cancer stem cells (BCSCs) 10, 15, 20, 25 µM 24 hours To evaluate the effect of psoralidin on cell viability, results showed that psoralidin significantly inhibited the growth of BCSCs with IC50 values ranging from 18-21 μM Br J Cancer. 2013 Nov 12;109(10):2587-96
MDA-MB-231 cells (ALDH+) 10, 15, 20, 25 µM 24 hours To evaluate the effect of psoralidin on cell viability, results showed that psoralidin significantly inhibited the growth of ALDH+ cells with IC50 values ranging from 18-21 μM Br J Cancer. 2013 Nov 12;109(10):2587-96
MDA-MB-231 cells (ALDH-/C0) 10, 15, 20, 25 µM 24 hours To evaluate the effect of psoralidin on cell viability, results showed that psoralidin significantly inhibited the growth of ALDH-/C0 cells with IC50 values ranging from 18-21 μM Br J Cancer. 2013 Nov 12;109(10):2587-96
DU-145 cells 45 µM 24 hours Psoralidin inhibited viability and induced apoptosis in DU-145 cells Apoptosis. 2010 Feb;15(2):153-61
MG63 cells 0–50 µM 24 or 48 hours PSO inhibited OS cell proliferation in a dose-dependent and time-dependent manner. Chin Med. 2023 Mar 31;18(1):34
143B cells 0–50 µM 24 or 48 hours PSO inhibited OS cell proliferation in a dose-dependent and time-dependent manner. Chin Med. 2023 Mar 31;18(1):34
HL-1 cardiomyocytes 20 µM 3 hours Psoralidin pretreatment significantly increased cell viability, reduced apoptosis rate, intracellular ROS generation, and LDH release. J Adv Res. 2022 Sep;40:249-261
DU-145 cells 45 µM 30 and 60 minutes Psoralidin inhibited both constitutive and epidermal growth factor (EGF)-induced EGFR activation and simultaneously triggered SAPK signaling, resulting in the induction of apoptosis in AIPC cells. Mol Cancer Ther. 2010 Sep;9(9):2488-96
PC-3 cells 60 µM 30 and 60 minutes Psoralidin inhibited both constitutive and epidermal growth factor (EGF)-induced EGFR activation and simultaneously triggered SAPK signaling, resulting in the induction of apoptosis in AIPC cells. Mol Cancer Ther. 2010 Sep;9(9):2488-96
Ichthyophthirius multifiliis theronts 0.8 mg/L or higher 4 hours Evaluate the killing effect of psoralidin on I. multifiliis theronts, results showed that at 0.8 mg/L or higher concentrations, all theronts were killed within 4 hours Int J Parasitol Drugs Drug Resist. 2015 Apr 21;5(2):58-64
Human lung adenocarcinoma cell lines (A549) 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300 µg/mL 48 hours To evaluate the cytotoxicity of psoralidin and its nanoformulation on A549 cells. Results showed that Ps-CS/BLs had an IC50 value of 3.56 ± 0.36 µg/mL, significantly lower than free psoralidin (48.94 ± 1.3 µg/mL). Polymers (Basel). 2023 Mar 15;15(6):1464
Human breast cancer cell lines (MCF-7) 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100, 300 µg/mL 48 hours To evaluate the cytotoxicity of psoralidin and its nanoformulation on MCF-7 cells. Results showed that Ps-CS/BLs had an IC50 value of 1.19 ± 0.24 µg/mL, significantly lower than free psoralidin (39.85 ± 1.1 µg/mL). Polymers (Basel). 2023 Mar 15;15(6):1464
HeLa cells 20-50 µM 48 hours To evaluate the cytotoxic and apoptotic activities of psoralidin in HeLa cells. Results showed that psoralidin induced apoptosis in a concentration-dependent manner, with 13.5 ± 1.2% apoptosis at 50 μM. Molecules. 2012 May 29;17(6):6449-64

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
BALB/c mice ADR-induced cardiotoxicity model Intraperitoneal injection 12.5, 25, 50 mg/kg Every two days, three times in total Psoralidin significantly increased the survival rate of ADR-injured mice, improved cardiac function indicators, and reduced myocardial fibrosis, oxidative stress, and apoptosis. J Adv Res. 2022 Sep;40:249-261
Goldfish (Carassius auratus) I. multifiliis infection model Water bath administration 2.5 mg/L 5 hours Evaluate the in vivo therapeutic effect of psoralidin on I. multi?liis infected gold?sh, results showed that 2.5 mg/L concentration for 5 hours significantly reduced the number of theronts released Int J Parasitol Drugs Drug Resist. 2015 Apr 21;5(2):58-64
Balb/c nude mice CTPE xenograft model Oral 20 mg/kg 5 days per week for 4-5 weeks Oral administration of Psoralidin significantly suppressed CTPE xenograft growth without observable toxicity. Tumours from Pso-treated animals showed decreased autophagic morphology, mesenchymal markers expression, and increased epithelial protein expression. Br J Cancer. 2017 Jun 27;117(1):56-64
Balb/c athymic nude mice ALDH+, CD44+/CD22− and ALDH− xenograft models Oral 25 mg/kg 5 days a week for 4 weeks Psoralidin significantly inhibited the growth of ALDH+, CD44+/CD22? and ALDH? tumors and inhibited Notch-1 mediated EMT activation. Mol Carcinog. 2017 Mar;56(3):1127-1136
BALB/c nude mice Orthotopic osteosarcoma mouse model Oral gavage 5, 10, or 20 mg/kg Every two days for three weeks PSO significantly inhibited osteosarcoma growth and metastasis. Chin Med. 2023 Mar 31;18(1):34
Mice PC-3 xenograft model Oral 50 mg/kg Not specified Psoralidin inhibited tumor growth and induced apoptosis Apoptosis. 2010 Feb;15(2):153-61
Nude mice PC-3 xenograft model Oral 50 mg/kg Five days a week for four weeks Psoralidin effectively suppressed PC-3 xenograft tumors by inhibiting EGFR-mediated survival signaling with a simultaneous induction of SAPK-mediated apoptotic events. Mol Cancer Ther. 2010 Sep;9(9):2488-96

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.97mL

0.59mL

0.30mL

14.87mL

2.97mL

1.49mL

29.73mL

5.95mL

2.97mL

References

 

Historical Records

Categories